NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Daré Bioscience, Inc. (DARE) Stock Analysis

Daré Bioscience, Inc. (DARE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

DARE

$0.69

−$0.00 (−0.15%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DARE with… →

DARE Key Statistics

As of Oct 21, 2026
Trading
Open
$0.68
Previous Close
$0.69
Day's Range
0.67–0.71
52-Week Range
0.67–3.78
Volume
24.19K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.01
Valuation
Market Cap
$13.53M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.91
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.71
Financials (FY)
Revenue (FY)
$1.03M+10,429.36%
Net Income (FY)
−$13.40M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.67M
1-Year Return
−67.70%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
505.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, DARE closed at $0.69, −67.70% over 1 year.

Daré Bioscience, Inc. (DARE) has a market capitalization of $13.53M.

In fiscal 2025, DARE reported revenue of $1.03M.

DARE Stock Return by Calendar Year

Daré Bioscience, Inc. (DARE) 10-year return: what $10,000 became

1 year
$10,000 $3,230
−67.70%
5 years
$10,000 $387
−96.13%
10 years
$10,000 $61
−99.39%

If you had invested $10,000 in Daré Bioscience, Inc. (DARE) 10 years ago, at the close on October 21, 2016, it would have been worth $61 at the close on October 21, 2026: −99.39% in total, −39.97% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−64.35%
2025−38.14%
2024−15.86%
2023−62.77%
2022−58.50%
2021+49.25%
2020+63.41%
2019+15.33%
2018−67.14%
2017−69.44%
2016 (partial year)−74.71%

As of October 21, 2026.

DARE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.03M−$13.40M−1,300.7%
2024$9.78K−$4.05M−41,430.9%
2023$2.81M−$30.16M−1,074.2%
2022$10.00M−$30.95M−309.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.03M$734.39K−$13.55M−$13.40M−1,300.7%
2024$9.78K—−$23.45M−$4.05M−41,430.9%
2023$2.81M—−$30.94M−$30.16M−1,074.2%
2022$10.00M—−$31.39M−$30.95M−309.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DARE Valuation vs Biotechnology Median

Median of 608 stocks
MetricDAREBiotechnology medianvs median
P/S ratio9.9113.3026% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Daré Bioscience, Inc. (DARE) carries a market capitalisation of $13.53M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 21.

The most recent close on file for DARE is $0.69, dated October 21, 2026. That is $0.00 (−0.15%) against the previous close. The 52-week range on file runs from $0.67 to $3.78. The latest close sits 2.69% above that 52-week low.

Financial Health

In fiscal 2025, Daré Bioscience, Inc. reported revenue of $1.03M. Against the prior fiscal year total of $9.78K, that is a change of +10,429.36%. The same year closed with a net loss of $13.40M. Trailing earnings per share are −0.71.

Across the 4 fiscal years on file, revenue moves from $10.00M in 2022 to $1.03M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 9.91. On price-to-sales that is 25.5% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.01. Annualized volatility over the trailing 10 years is 116.3%. Over the trailing twelve months the total return is −67.70%. Across 10 years the annualized return works out at −39.97%.

Growth & Income

The record shows no dividend for DARE.

So far in 2026 the total return is −64.35%. Across the complete calendar years on file, 2020 returned +63.41% and 2017 returned −69.44%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Daré Bioscience, Inc. (DARE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Daré Bioscience, Inc. DARE $13.53M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Daré Bioscience, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Daré Bioscience, Inc.

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Visit website →